MEK Inhibitor PD-325901 To Treat Advanced Non-Small Cell Lung Cancer
Status:
Terminated
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
MEK is a critical member of the MAPK pathway involved in growth and survival of cancer cells.
PD-325901 is a new drug designed to block this pathway and kill cancer cells. The purpose of
this study is to study the effectiveness of PD-325901 in patients with non-small cell lung
cancer. PD-325901 will be given by mouth as a pill twice a day, CT scans will be done and
biopsies of a tumor and a blood sample will be taken before treatment to examine the how
genes affect tumor response to the study medication. Blood samples will be taken to measure
the amount of drug in the blood.